Melatonin (Slenyto) for the treatment of insomnia in children and adolescents aged 2-18 with autism spectrum disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient

Scottish Medicines Consortium
Record ID 32018000969
Authors' objectives: To assess clinical and cost effectiveness.
Project Status: Completed
Year Published: 2021
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: Scotland
MeSH Terms
  • Attention Deficit Disorder with Hyperactivity
  • Autism Spectrum Disorder
  • Melatonin
  • Sleep Initiation and Maintenance Disorders
  • Child
  • Adolescent
  • Smith-Magenis Syndrome
Organisation Name: Scottish Medicines Consortium (SMC)
Contact Address: Delta House | 50 West Nile Street
Contact Name: Susan Downie
Contact Email:
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.